Breast Reconstruction with Implant in India and UAE | Complete Patient Guide

• IDEAL CANDIDATES:

• Women who have undergone or are planning total mastectomy (therapeutic or risk-reducing/prophylactic) for breast cancer (Stage I–III) or BRCA1/BRCA2 pathogenic variant carriers

• Patients with adequate mastectomy skin flap thickness and viability confirmed by ICG perfusion mapping

• Adequate body habitus: BMI ≤ 35 kg/m²; morbid obesity (BMI > 40) significantly increases complication risk

• Non-smokers, or patients who have ceased smoking for a minimum of 6 weeks prior to surgery (nicotine quantified by urinary cotinine assay)

• Patients who have completed neoadjuvant chemotherapy with ≥ 4 weeks' washout and haematological recovery (ANC > 1.5 × 10⁹/L; platelets > 100 × 10⁹/L)

• Patients who do NOT require immediate post-mastectomy radiotherapy (PMRT) or where radiation is deferred — active PMRT is a relative contraindication to primary implant placement due to 3–4× higher capsular contracture and implant loss rates

• REQUIRED PRE-OPERATIVE DIAGNOSTICS:

• Bilateral mammogram and breast MRI (gadolinium-enhanced) or PET-CT (18F-FDG) to confirm disease staging and contralateral breast status

• Echocardiogram (ECHO) and 12-lead ECG if prior anthracycline (doxorubicin, epirubicin) chemotherapy (cardiotoxicity screening)

• Full blood count, coagulation profile (PT/INR/aPTT), HbA1c (diabetes screening), liver and renal function panel

• Nutritional assessment: serum albumin, pre-albumin (hypoalbuminaemia <3.5 g/dL associated with impaired wound healing)

• Anaesthetic fitness: ASA Physical Status classification; cardiopulmonary exercise testing (CPET) for high-risk patients

• Genetic counselling and BRCA panel result review (relevant for prophylactic reconstruction decisions)

• CONTRAINDICATIONS:

• Active local or systemic infection

• Uncontrolled diabetes (HbA1c > 8.5%) — defer until optimised

• Active smoking within 6 weeks of surgery

• Prior chest wall radiation without adequate soft-tissue coverage (consider latissimus dorsi or DIEP flap instead)

• Known allergy or hypersensitivity to silicone (extremely rare; patch-test and allergen panel required)

• Active autoimmune connective tissue disease (e.g., scleroderma) — relative contraindication; multidisciplinary rheumatology review mandatory

• Metastatic (Stage IV) disease where systemic prognosis limits reconstruction benefit (case-by-case oncological MDT decision)

STAGE 1: TISSUE EXPANDER-BASED TWO-STAGE RECONSTRUCTION (MOST COMMON)

At the time of mastectomy, a textured or smooth saline-filled tissue expander (e.g., Mentor CPX4, Allergan Natrelle 133) is placed in the sub-pectoral or pre-pectoral plane, partially inflated, and supported inferolaterally with an acellular dermal matrix (ADM) sling. Over 3–6 months of outpatient expansion (30–60 mL saline added every 2–3 weeks via a transcutaneous port), the skin envelope is gradually stretched to target volume. At Stage 2 (day-surgery or 1-night admission), the expander is removed and exchanged for a permanent cohesive silicone gel implant, with simultaneous refinements to the inframammary fold and symmetry procedures on the contralateral breast if indicated.

STAGE 2: DIRECT-TO-IMPLANT (DTI) SINGLE-STAGE RECONSTRUCTION

Enabled by real-time ICG perfusion angiography (SPY Elite/SPY PHI system), DTI places a permanent implant immediately after mastectomy in a single operative episode. ADM (AlloDerm, Braxon pre-pectoral matrix) creates a complete implant pocket, eliminating the need for muscular coverage. Ideal for skin-sparing or nipple-sparing mastectomy patients with DIEP-unfavourable anatomy, DTI reduces total treatment time by 3–6 months and avoids a second general anaesthetic. Contraindicated when mastectomy flap perfusion is compromised on ICG imaging.

PRE-PECTORAL vs. SUB-PECTORAL PLANE

Pre-pectoral placement (implant anterior to pectoralis major, supported entirely by ADM) eliminates the animation deformity (implant displacement with pectoralis contraction) characteristic of sub-pectoral reconstruction, preserves pectoralis muscle function, reduces post-operative pain, and shortens recovery. It requires robust ADM support and high-quality skin flaps. Sub-pectoral ('dual-plane') placement remains preferred when skin flaps are thin, poorly perfused, or post-irradiated.

IMPLANT SELECTION

• Form-stable highly cohesive silicone gel ('gummy bear') implants: anatomical (teardrop) or round profiles; 5th-generation devices (Motiva Ergonomix, Mentor MemoryShape, Allergan Natrelle 410) with progressive gel cohesivity. Lower bleed rate, shape retention on rupture, and superior upper-pole aesthetics compared to older generation devices.

• Smooth vs. macro-textured vs. nanotextured surfaces: following global regulatory reviews on BIA-ALCL (Breast Implant-Associated Anaplastic Large Cell Lymphoma) linked to macro-textured/polyurethane devices, most GAF partner centres now use smooth or nanotextured (SilkSurface, Motiva) implants with significantly lower BIA-ALCL risk profiles.

• Saline implants: less commonly used in reconstruction; useful when MRI surveillance for rupture is prioritised.

NIPPLE-AREOLA COMPLEX (NAC) RECONSTRUCTION

Performed as a tertiary procedure 3–4 months after final implant exchange: local flap techniques (skate flap, C-V flap, star flap) reconstruct the nipple projection; medical tattooing by specialist paramedical tattoo artists recreates areola pigmentation. Some centres offer 3D areola tattooing as an outpatient alternative to surgical NAC reconstruction.

FAT GRAFTING (LIPOFILLING / STRUCTURAL FAT TRANSFER)

Autologous fat harvested by low-pressure liposuction (Coleman technique) is processed and micro-injected to correct contour irregularities, rippling, and upper-pole hollowing around the implant. Typically performed as an adjunct 6–12 months post-reconstruction. Multiple sessions may be required.

ROBOTIC AND ENDOSCOPIC-ASSISTED APPROACHES

A small number of GAF partner centres offer robot-assisted (da Vinci platform) or endoscopic axillary-approach reconstruction for select nipple-sparing mastectomy cases, minimising visible chest wall scarring — particularly valued by patients of South and East Asian heritage with keloid tendency.

PRE-OPERATIVE PHASE (4–8 WEEKS BEFORE SURGERY)

• Step 1 — Virtual Consultation: Upload medical records, pathology reports, operative notes, and imaging to GAF Healthcare's secure patient portal. A GAF case manager schedules a video consultation with a reconstructive surgeon within 48 hours.

• Step 2 — Medical Clearance: Complete the required diagnostic workup (ECHO, PET-CT or MRI, blood panel, HbA1c, coagulation profile) either at home or upon arrival at the destination hospital. Anaesthetic pre-assessment conducted.

• Step 3 — Implant and Technique Selection: 3D breast imaging (Vectra XT volumetric simulation) used in partner centres to model expected outcomes across implant sizes and profiles. Surgical plan documented and consented.

• Step 4 — Pre-operative Optimisation: Smoking cessation confirmed (urinary cotinine test), nutritional supplementation (Vitamin C, zinc, high-protein diet), cessation of anticoagulants/NSAIDs/herbal supplements 10–14 days pre-op. HbA1c optimised to < 7.5% in diabetic patients.

• Step 5 — Arrival & Admission: GAF Healthcare coordinates airport pickup, hotel or hospital accommodation for patient and attendant. Pre-operative skin chlorhexidine wash protocol initiated 48 hours before surgery.

INTRA-OPERATIVE PHASE

• Step 6 — Anaesthesia: General anaesthesia with enhanced recovery after surgery (ERAS) protocol: total intravenous anaesthesia (TIVA) preferred to reduce post-operative nausea; multimodal regional anaesthesia (pectoralis nerve block — PECS I/II block) for opioid-sparing analgesia.

• Step 7 — Procedure: Duration 2–4 hours (single-stage DTI) or 3–5 hours (two-stage with simultaneous expander placement at mastectomy). ICG perfusion angiography performed intraoperatively to assess flap viability before implant placement. ADM secured and implant/expander positioned. Closed-suction drains (Jackson-Pratt) placed.

• Step 8 — Immediate Post-operative: Patient monitored in recovery room and high-dependency unit for first 12–24 hours. Intravenous antibiotics (cephalosporin class), DVT prophylaxis (LMWH — enoxaparin), and compression stockings initiated.

INPATIENT RECOVERY (DAYS 1–5)

• Step 9 — Days 1–2: Drains output monitored (< 30 mL/24 h = threshold for removal). Gradual mobilisation with physiotherapy. Oral analgesia escalated (paracetamol + ibuprofen + gabapentin multimodal regimen; opioids minimised). Wound inspected daily.

• Step 10 — Days 3–5: Drains removed when output criteria met. Supportive surgical bra fitted. Patient discharged with written drain and wound care instructions.

EARLY OUTPATIENT RECOVERY (WEEKS 1–4)

• Step 11 — Week 1–2: Suture removal or wound review at GAF partner clinic on post-op day 10–14. Arm elevation restricted (no overhead lifting > 0.5 kg). Sleep in semi-reclined position. Scar management with silicone gel strips initiated from week 2.

• Step 12 — Week 3–4: Gradual return to light activities of daily living. Walking encouraged. No driving for 4 weeks. First expander inflation appointment at week 3–4 (if two-stage protocol).

• Step 13 — Fit-to-Fly Assessment: GAF medical team conducts clinical review at week 4–5. Fitness for international travel confirmed when: drains removed, wounds healed, no haematoma/seroma, DVT risk assessed (CAPRINI score). Compression garment and LMWH prophylaxis prescribed for long-haul flights (>4 hours).

LONG-TERM MILESTONES

• 6 weeks: Return to low-impact exercise (walking, stationary cycling)

• 3 months: Return to full gym activities; Stage 2 implant exchange planning begins (two-stage patients)

• 6 months: Fat grafting adjunct procedures if required; nipple reconstruction planning

• 12 months: Final aesthetic assessment; contralateral symmetry procedure if desired; BREAST-Q outcome scoring

• Annual: MRI surveillance (non-contrast for silicone integrity assessment; recommended every 5–6 years per FDA 2021 guidance, or annually post-radiation)